BAVARIAN NORDIC A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 156.4 DKK | -3.75% |
|
+2.72% | -11.78% |
| Apr. 30 | Bavarian Nordic Books EUR65 Million Order for Smallpox Vaccine | MT |
| Apr. 29 | Bavarian Nordic A/S Receives EUR 65 Million Contract to Supply Smallpox Vaccines for EU Strategic Reserve | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 5.23B 753M | Sales 2025 * | 5.05B 727M | Capitalization | 12.67B 1.82B |
|---|---|---|---|---|---|
| Net income 2024 * | 659M 94.9M | Net income 2025 * | 848M 122M | EV / Sales 2024 * | 2.42 x |
| Net cash position 2024 * | 32.83M 4.73M | Net cash position 2025 * | 849M 122M | EV / Sales 2025 * | 2.34 x |
| P/E ratio 2024 * |
19.1
x | P/E ratio 2025 * |
15
x | Employees | 1,379 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.85% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bavarian Nordic A/S
More press releases
More news
| 1 day | +1.66% | ||
| 1 week | +5.86% | ||
| Current month | +5.86% | ||
| 1 month | +6.00% | ||
| 3 months | +3.70% | ||
| 6 months | +19.84% | ||
| Current year | -8.42% |
1 week
151.90
162.60
1 month
143.40162.60
Current year
143.40182.50
1 year
125.55222.00
3 years
115.20411.00
5 years
103.20411.00
10 years
103.20444.00
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Chaplin
CEO | Chief Executive Officer | 57 | 98-12-31 |
Henrik Juuel
DFI | Director of Finance/CFO | 59 | 18-10-31 |
Russell Thirsk
COO | Chief Operating Officer | 56 | 22-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 73 | 10-04-26 | |
| Director/Board Member | 57 | 22-12-31 | |
Frank Verwiel
BRD | Director/Board Member | 62 | 16-04-19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 0 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 156.5 | -3.69% | 827 905 |
| 24-05-07 | 162.5 | +1.66% | 391,327 |
| 24-05-06 | 159.8 | +2.73% | 433,350 |
| 24-05-03 | 155.6 | +2.44% | 534,032 |
| 24-05-02 | 151.9 | -0.33% | 364,018 |
Delayed Quote Nasdaq Copenhagen, May 07, 2024 at 10:59 am EDT
More quotes
Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases.
Net sales by revenue source are divided between sales of products (97.8%) and services (2.2%).
Net sales are distributed geographically as follows: the United States (36.5%), Canada (22%), France (10.5%), Germany (10.1%), Spain (6.1%), Australia (4.8%), Switzerland ( 1.5%), Sweden (1%), Chile (0.9%), Taiwan (0.8%), the United Kingdom (0.6%), Hong Kong (0.2%), Saudi Arabia (0.1%), and others (4.9%).
Sector
Pharmaceuticals
Calendar
2024-05-07
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
162.5
DKK
Average target price
262
DKK
Spread / Average Target
+61.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.42% | 1.83B | |
| +33.43% | 700B | |
| +26.43% | 569B | |
| -5.12% | 358B | |
| +19.59% | 330B | |
| +4.89% | 287B | |
| +14.32% | 236B | |
| +5.79% | 202B | |
| -9.49% | 197B | |
| +4.26% | 161B |
- Stock Market
- Equities
- BAVA Stock